Related Experiment Videos

Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening

Michael P Mah1, Steven L Clark, Efe Akhigbe

  • 1Hospital Corporation of America, Nashville, Tennessee, USA.

Pediatrics
|April 7, 2010
PubMed

Insights

Universal predischarge screening for neonatal bilirubin significantly reduces dangerous hyperbilirubinemia. This prevention program lowered high bilirubin levels in newborns, decreasing risks of bilirubin encephalopathy.

Area of Science:

  • Neonatal Medicine
  • Public Health
  • Pediatrics

Background:

  • Hyperbilirubinemia is a common condition in newborns.
  • Severe hyperbilirubinemia can lead to bilirubin encephalopathy, a serious neurological complication.
  • Effective screening and prevention strategies are crucial for newborn health.

Purpose of the Study:

  • To evaluate the efficacy of universal predischarge neonatal bilirubin screening.
  • To assess the impact of this screening program on reducing dangerous hyperbilirubinemia in a large, diverse population.
  • To analyze trends in severe hyperbilirubinemia and phototherapy use before and after screening implementation.

Main Methods:

  • A 5-year prospective study involving over 1 million neonates across 116 hospitals.
  • Data collected on serum bilirubin levels and phototherapy use.
  • Comparison of outcomes before and after the systemwide implementation of universal predischarge neonatal bilirubin screening.

Main Results:

  • Universal screening significantly decreased the incidence of total bilirubin levels between 25.0–29.9 mg/dL (from 43 to 27 per 100,000) and ≥30.0 mg/dL (from 9 to 3 per 100,000).
  • The observed reductions in severe hyperbilirubinemia were statistically significant (P = .0019 and P = .0051).
  • A slight, statistically significant increase in phototherapy use was noted alongside the decline in severe hyperbilirubinemia.

Conclusions:

  • Universal predischarge neonatal bilirubin screening is an effective prevention strategy.
  • This screening program significantly reduces the incidence of bilirubin levels posing a risk for bilirubin encephalopathy.
  • Implementing comprehensive prevention programs, including universal screening, is vital for newborn safety.
Abstract

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...